A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

High activity of human cytomegalovirus in patients with Sjögren's disease




TekijätPantalone, Mattia Russel; Xu, Xinling; Almazán, Nerea Martín; Gerstner, Christina; Fischer, Marie; Kvarnström, Marika; Söderberg-Nauclér, Cecilia; Wahren-Herlenius, Marie; Rahbar, Afsar

KustantajaElsevier BV

Julkaisuvuosi2025

JournalClinical Immunology

Tietokannassa oleva lehden nimiClinical Immunology

Artikkelin numero110545

Vuosikerta279

ISSN1521-6616

eISSN1521-7035

DOIhttps://doi.org/10.1016/j.clim.2025.110545

Verkko-osoitehttps://www.sciencedirect.com/science/article/pii/S1521661625001202?via%3Dihub

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/499246645


Tiivistelmä

Sjögren's disease (SD) is a chronic autoimmune disease characterized by immune-mediated damage to salivary and lacrimal glands. This study aimed to explore the potential link between SD and human cytomegalovirus (HCMV), by analyzing presence of HCMV proteins in salivary gland tissue specimens and prevalence of HCMV-specific antibodies in serum samples from SD patients and controls. HCMV-immediate early (IE) and late proteins (LA and pp65) were highly abundant in tissue specimens from SD patients (88.9 %, 69.2 %, 45.8 %, respectively), and less abundant in patients with Sicca symptoms without SD (70.5 %, 20.0 %, 12.5 %, respectively). Samples in the SD group were also positive at higher scores for the HCMV proteins than Sicca symptom patients without SD. IgM prevalence was higher in SD patients than in healthy controls (32.1 % vs. 13.4 %, P = 0.04) and HCMV-IgG titers were higher (P < 0.0001). Understanding the potential role of HCMV in SD pathogenesis may contribute to advancements in disease prevention and treatment.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This study was supported by The Swedish Medical Research Council Grant # 2022–02724 and 2021–02503 and was financially supported by InFLAMES Flagship Programme of the Academy of Finland (decision number: 337530).


Last updated on 2025-15-08 at 15:49